ArticleCancers2020
Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.Critical reviews in oncology/hematology · 2021Pooled it
- Ultra-Low-Dose Inhalation of Melphalan as an Additional Treatment for COVID-19-Associated Pneumonia.Journal of clinical medicine · 2025Article
- Cancer management during the COVID-19 world pandemic.Cancer immunology, immunotherapy : CII · 2023Review
- Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis.Translational oncology · 2023Article
- Impact of COVID-19 on Cancer-Related Care in the United States: An Overview.Current oncology (Toronto, Ont.) · 2023Review
- The Impact of COVID-19 Infection in Cancer 2020-2021.Cancers · 2022Article
- Low skeletal muscle radiodensity and neutrophil-to-lymphocyte ratio as predictors of poor outcome in patients with COVID-19.Scientific reports · 2022Article
- Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Review
- Clinical characteristics of COVID-19-infected cancer patients, Isfahan, Iran.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Article
- Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis.Infectious agents and cancer · 2021Article
- Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer.JAMA oncology · 2021Article
- Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors.Experimental gerontology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCancer patients present a distinct vulnerability to COVID-19. It is unclear if chemotherapy could accentuate the overall risk in these patients.
methodsWe performed a retrospective analysis linking COVID-19 data and oncological information systems to compare lethality in patients undergoing cytotoxic chemotherapy before COVID-19. We considered patients who received chemotherapy in the last 30 days as in "active treatment", and patients who did not receive drugs in this period as "non-active treatment" for propensity-score pair matching. We also tested the influence of baseline variables in our results in a multivariate model.
results66.1% (162/246) of patients in matched active chemotherapy died vs. 70.2% (172/246) in the matched non-active chemotherapy group. The risk of death was positively associated with palliative intent of treatment and hematologic neoplasms. Being in active chemotherapy was not associated with increased mortality compared to non-active treatment. We also noted in exploratory propensity-score matchings that the use of alkylating agents (odds ratio [OR] 0.38, 95% confidence interval [CI], 0.21-0.70) and topoisomerase II inhibitors (OR 0.28, 95% CI 0.14-0.56) were protective factors.
conclusionsThis study does not demonstrate an increase in mortality for cancer patients under active cytotoxic chemotherapy with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.